The Our Way Forward survey asked patients and healthcare providers to share their experiences coping with, or treating, ovarian cancer. The results indicate that regardless of the stage of ovarian cancer, there is uncertainty among patients about what to expect after diagnosis – whether they are initially diagnosed or actively seeking greater resources and connections with others to lessen the burden of the disease.
The survey results revealed a number of key takeaways regarding the dialogue between women with ovarian cancer and their healthcare providers.
felt that ovarian cancer has had a severe or very severe impact on their lives.
For those women who have experienced recurrence.
report the thought of cancer returning can be overwhelming.
who are in treatment or who have been treated admit that they find not being sure of the path forward after diagnosis to be very or extremely challenging.
are unsure if, or do not feel that, they give their ovarian cancer patients all of the information they need about ovarian cancer.
say they discuss expectations for treatment often or at every visit.
say they discuss recurrence often or at every visit.
say they discuss the emotional challenges of ovarian cancer often or at every visit.
Join us for a free ovarian cancer educational or storytelling event near you. RSVP today!
September 20, 2018
Registration: 5:15 PM
Start Time: 6:00 PM
World Cafe Live
3025 Walnut Street
Philadelphia, PA 19104
Please email email@example.com to RSVP
Seats are limited | RSVP is required
The Our Way Forward survey was conducted online in the U.S. by Harris Poll on behalf of TESARO, Inc. between April 13 and May 2, 2017, among 254 women 18+ years of age living in the U.S. who have been diagnosed with ovarian cancer. Survey respondents were selected from individuals who had agreed to participate in surveys through the Harris Poll and their partners or were recruited to participate by patient advocacy organizations, NOCC and OCRFA. Results are not weighted and are therefore representative of only those surveyed. A parallel survey was conducted between April 17 and May 5, 2017, among 232 physicians who treat ovarian cancer patients in the U.S. consisting of 201 medical oncologists and 31 gynecologic oncologists. Survey respondents were selected from physicians who had agreed to participate in surveys through the Harris Poll and their partners. Weights for gender, by years in practice, and region were applied to align the data with the population parameters for medical oncologists and gynecologic oncologists, separately. A post weight was then applied to combine the two medical specialty groups in proper proportion for the total.